Microbot Medical Inc. Elects Directors, Appoints Officers

TL;DR

Microbot Medical shakes up leadership and gets shareholder votes on Dec 17th.

AI Summary

Microbot Medical Inc. announced on December 17, 2024, a series of significant corporate actions. These include the election of new directors, the appointment of new officers, and the approval of compensatory arrangements for certain officers. Additionally, the company submitted matters to a vote of its security holders and filed financial statements and exhibits.

Why It Matters

Changes in board and officer composition can signal shifts in company strategy and governance, potentially impacting future performance and shareholder value.

Risk Assessment

Risk Level: medium — Changes in leadership and corporate governance can introduce uncertainty and potential strategic shifts.

Key Players & Entities

• Microbot Medical Inc. (company) — Registrant
• December 17, 2024 (date) — Earliest event reported

FAQ

Key Financial Figures

• $0.01 — nge on which registered Common Stock, $0.01 par value MBOT NASDAQ Capital Marke

Filing Documents

• form8-k.htm (8-K) — 62KB
• 0001493152-24-050799.txt ( ) — 237KB
• mbot-20241217.xsd (EX-101.SCH) — 3KB
• mbot-20241217_lab.xml (EX-101.LAB) — 33KB
• mbot-20241217_pre.xml (EX-101.PRE) — 24KB
• form8-k_htm.xml (XML) — 4KB

02

Item 5.02 Departure of Directors or Principal Officers; Election of Directors; Appointment of Principal Officers David J. Wilson, who was elected at the Annual Meeting of Stockholders (the "Annual Meeting") of Microbot Medical Inc. (the "Company"), held on December 17, 2024, to serve as a Class III director for a three-year term commencing on December 17, 2024, was subsequently appointed by the Board of Directors of the Company to serve as a member of the Company's Audit Committee and Compensation Committee. He fills the committee vacancies created when Yoseph Bornstein's term as a director expired at the Annual Meeting. Since March 2022, Mr. Wilson has been the Chief Executive Officer and a director of InnovHeart Corporation, a private company developing transcatheter mitral valve replacement systems to treat patients suffering from mitral valve disease. From September 2017 to October 2021, he was the President of Global Plasma at Haemonetics Corporation where he led the global commercialization of a next generation plasma collection system. He dedicated two decades in roles of increasing responsibility with various Johnson and Johnson (J&J) companies, including as the Worldwide President of Cordis. In this role, he led the global integration of Cordis into Cardinal Health and rejuvenated the product portfolio through business development deals. Mr. Wilson held other leadership roles at J&J companies, namely President of Mentor, Vice President of Ethicon R&D and Vice President of Ethicon Biosurgicals. Earlier in his tenure with J&J, he attained senior leadership roles at Cordis Endovascular as Vice President of R&D and Regional Director of Sales. He is the holder of 10 medical device patents and has served as a Board member of several educational and healthcare institutions in the US. His education includes a Bachelor of Mechanical Engineering from Auburn University, a Master of Science in Biomedical Engineering from the University of Alabama at Birmingham and

Financial Statements

Financial Statements and Exhibits Exhibit Description 104 Cover Page Interactive Data File (embedded within the Inline XBRL document)

SIGNATURES

SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized. MICROBOT MEDICAL INC. By: /s/ Harel Gadot Name: Harel Gadot Title: Chief Executive Officer, President and Chairman Date: December 19, 2024

View Full Filing

View this 8-K filing on SEC EDGAR